Traders sold shares of Johnson & Johnson (NYSE:JNJ) on strength during trading on Wednesday. $94.00 million flowed into the stock on the tick-up and $232.30 million flowed out of the stock on the tick-down, for a money net flow of $138.30 million out of the stock. Of all stocks tracked, Johnson & Johnson had the 2nd highest net out-flow for the day. Johnson & Johnson traded up $0.29 for the day and closed at $142.89

Several analysts have issued reports on JNJ shares. Cowen reissued an “outperform” rating and set a $155.00 target price (up from $147.00) on shares of Johnson & Johnson in a research note on Wednesday, October 18th. UBS reissued a “buy” rating and set a $148.00 target price on shares of Johnson & Johnson in a research note on Thursday, August 31st. Jefferies Group boosted their target price on shares of Johnson & Johnson from $157.00 to $160.00 and gave the company a “buy” rating in a research note on Monday, October 16th. Zacks Investment Research raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Wednesday, October 4th. Finally, Credit Suisse Group set a $154.00 target price on shares of Johnson & Johnson and gave the company an “outperform” rating in a research note on Thursday, October 19th. Four investment analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $145.04.

The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36. The stock has a market capitalization of $379,175.44, a P/E ratio of 19.77, a price-to-earnings-growth ratio of 2.87 and a beta of 0.80.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The business had revenue of $19.65 billion for the quarter, compared to the consensus estimate of $19.29 billion. During the same period in the prior year, the business posted $1.68 earnings per share. Johnson & Johnson’s revenue for the quarter was up 10.3% compared to the same quarter last year. analysts forecast that Johnson & Johnson will post 7.28 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th were paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.35%. The ex-dividend date was Monday, November 27th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 58.33%.

Several hedge funds and other institutional investors have recently bought and sold shares of JNJ. Lenox Wealth Advisors Inc. boosted its holdings in Johnson & Johnson by 0.6% in the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after purchasing an additional 5 shares in the last quarter. Landmark Financial Advisors LLC boosted its holdings in Johnson & Johnson by 0.4% in the second quarter. Landmark Financial Advisors LLC now owns 1,962 shares of the company’s stock worth $259,000 after purchasing an additional 7 shares in the last quarter. Paradigm Financial Advisors LLC boosted its holdings in Johnson & Johnson by 0.3% in the second quarter. Paradigm Financial Advisors LLC now owns 2,649 shares of the company’s stock worth $350,000 after purchasing an additional 9 shares in the last quarter. Premier Asset Management LLC boosted its holdings in Johnson & Johnson by 0.4% during the second quarter. Premier Asset Management LLC now owns 2,749 shares of the company’s stock valued at $363,000 after acquiring an additional 12 shares during the period. Finally, Lbmc Investment Advisors LLC boosted its holdings in Johnson & Johnson by 0.4% during the second quarter. Lbmc Investment Advisors LLC now owns 3,718 shares of the company’s stock valued at $492,000 after acquiring an additional 14 shares during the period. 65.89% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Investors Sell Shares of Johnson & Johnson (JNJ) on Strength (JNJ)” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://www.thecerbatgem.com/2017/12/13/investors-sell-shares-of-johnson-johnson-jnj-on-strength-jnj.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.